April 23, 2018 / 8:48 PM / 4 months ago

BRIEF-EMA Validates Type II Variation For Merck's Keytruda In Combination With Pemetrexed And Platinum Chemotherapy

April 23 (Reuters) - Merck & Co Inc:

* EUROPEAN MEDICINES AGENCY VALIDATES TYPE II VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC NONSQUAMOUS NSCLC, BASED ON PHASE 3 KEYNOTE-189 TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below